Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Natalizumab + Prednisone for Acute GI GVHD
NCT02176031Phase 2Completed
- Sponsor
- Dana-Farber Cancer Institute
- Start
- Jan 2015
- Primary completion
- Feb 2019
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of natalizumab in Acute Graft-Versus-Host Disease (aGvHD), sponsored by Dana-Farber Cancer Institute. Started Jan 2015; status: completed.
02
Drugs
natalizumab
03
Conditions
Acute Graft-Versus-Host Disease (aGvHD)
Beyond the preview
Go deeper on NCT02176031.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02176031.